JP7663250B2 - ラッサウイルスワクチン - Google Patents

ラッサウイルスワクチン Download PDF

Info

Publication number
JP7663250B2
JP7663250B2 JP2022516041A JP2022516041A JP7663250B2 JP 7663250 B2 JP7663250 B2 JP 7663250B2 JP 2022516041 A JP2022516041 A JP 2022516041A JP 2022516041 A JP2022516041 A JP 2022516041A JP 7663250 B2 JP7663250 B2 JP 7663250B2
Authority
JP
Japan
Prior art keywords
sequence
protein
flavivirus
seq
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547695A (ja
JP2022547695A5 (https=
Inventor
ダルマイヤー，カイ
レメンス，ビクター
ネイツ，ヨハン
フェリペ，ロレーナ サンチェス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of JP2022547695A publication Critical patent/JP2022547695A/ja
Publication of JP2022547695A5 publication Critical patent/JP2022547695A5/ja
Application granted granted Critical
Publication of JP7663250B2 publication Critical patent/JP7663250B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022516041A 2019-09-13 2020-09-11 ラッサウイルスワクチン Active JP7663250B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197202.5 2019-09-13
EP19197202 2019-09-13
PCT/EP2020/075541 WO2021048402A1 (en) 2019-09-13 2020-09-11 Lassavirus vaccines

Publications (3)

Publication Number Publication Date
JP2022547695A JP2022547695A (ja) 2022-11-15
JP2022547695A5 JP2022547695A5 (https=) 2023-09-14
JP7663250B2 true JP7663250B2 (ja) 2025-04-16

Family

ID=68137784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516041A Active JP7663250B2 (ja) 2019-09-13 2020-09-11 ラッサウイルスワクチン

Country Status (8)

Country Link
US (1) US12558410B2 (https=)
EP (1) EP4041300A1 (https=)
JP (1) JP7663250B2 (https=)
CN (1) CN114728054A (https=)
AU (1) AU2020346382A1 (https=)
BR (1) BR112022004378A2 (https=)
WO (1) WO2021048402A1 (https=)
ZA (1) ZA202203730B (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042014A1 (en) 2003-10-29 2005-05-12 The University Of Queensland West nile virus vaccine
JP5779352B2 (ja) * 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
GB201307528D0 (en) 2013-04-26 2013-06-12 Univ Leuven Kath Bacterial artificial chromosomes
BR102016018430A2 (pt) * 2016-08-10 2018-02-27 Fundação Oswaldo Cruz Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivírus e/ou outros patógenos.
WO2019018501A1 (en) 2017-07-18 2019-01-24 Geovax Inc. COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vaccine，2011年，Vol.29, No.6，pp.1248-1257

Also Published As

Publication number Publication date
BR112022004378A2 (pt) 2022-06-07
EP4041300A1 (en) 2022-08-17
CN114728054A (zh) 2022-07-08
US20220378903A1 (en) 2022-12-01
JP2022547695A (ja) 2022-11-15
ZA202203730B (en) 2025-09-25
US12558410B2 (en) 2026-02-24
AU2020346382A1 (en) 2022-04-21
WO2021048402A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
AU2009223727B2 (en) Replication-defective flavivirus vaccines and vaccine vectors
US11638750B2 (en) Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein
US20250099568A1 (en) Chimeric Flavivirus Lyssavirus Vaccines
Timofeev et al. Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus
CN111683679A (zh) 具有异源抗原的活的减毒黄病毒
JP7663250B2 (ja) ラッサウイルスワクチン
JP2019535291A (ja) プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン
US12545709B2 (en) Chimeric filovirus vaccines
RU2816136C2 (ru) Химерные вакцины на основе вирусов родов flavivirus и lyssavirus
OA20740A (en) Lassavirus vaccines.
US20220168412A1 (en) Chimeric Zika-Japanese Encephalitis Virus
OA20659A (en) Chimeric filovirus vaccines.
WO2021262095A1 (en) Chimeric viral vaccine
US11351240B2 (en) Chimeric yellow fever ZIKA virus strain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230906

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250328

R150 Certificate of patent or registration of utility model

Ref document number: 7663250

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150